Media headlines about CareDx (NASDAQ:CDNA) have been trending somewhat positive on Saturday, Accern Sentiment reports. Accern scores the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. CareDx earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 45.5602126880444 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Shares of CareDx (NASDAQ:CDNA) traded down $0.06 during trading on Friday, reaching $5.71. 94,916 shares of the company’s stock were exchanged, compared to its average volume of 177,313. The company has a market capitalization of $165.04, a P/E ratio of -3.15 and a beta of 0.70. The company has a debt-to-equity ratio of -124.53, a current ratio of 0.55 and a quick ratio of 0.35. CareDx has a fifty-two week low of $0.76 and a fifty-two week high of $7.98.
A number of analysts recently weighed in on CDNA shares. Zacks Investment Research lowered shares of CareDx from a “buy” rating to a “hold” rating in a research note on Thursday, January 11th. ValuEngine lowered shares of CareDx from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th. Finally, HC Wainwright started coverage on shares of CareDx in a research note on Monday, November 27th. They issued a “buy” rating and a $12.00 price objective for the company. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $8.65.
In other CareDx news, COO Mitchell J. Nelles sold 10,948 shares of the business’s stock in a transaction dated Thursday, November 30th. The shares were sold at an average price of $7.17, for a total value of $78,497.16. Following the completion of the transaction, the chief operating officer now directly owns 84,225 shares in the company, valued at $603,893.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider James P. Yee sold 29,197 shares of the business’s stock in a transaction dated Friday, December 8th. The stock was sold at an average price of $7.00, for a total transaction of $204,379.00. Following the completion of the transaction, the insider now owns 74,795 shares of the company’s stock, valued at $523,565. The disclosure for this sale can be found here. Insiders own 5.40% of the company’s stock.
TRADEMARK VIOLATION WARNING: “CareDx (CDNA) Earns Media Sentiment Score of 0.11” was posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://www.thelincolnianonline.com/2018/02/17/caredx-cdna-earns-media-sentiment-score-of-0-11.html.
CareDx Company Profile
CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.